Albemarle Co. (NYSE:ALB) – Jefferies Group decreased their FY2019 earnings per share (EPS) estimates for Albemarle in a report released on Tuesday. Jefferies Group analyst L. Alexander now anticipates that the specialty chemicals company will earn $5.75 per share for the year, down from their previous forecast of $6.00. Jefferies Group currently has a “Buy” rating and a $120.00 price objective on the stock. Jefferies Group also issued estimates for Albemarle’s FY2021 earnings at $8.20 EPS.

Albemarle (NYSE:ALB) last posted its earnings results on Monday, February 27th. The specialty chemicals company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Albemarle had a net margin of 6.92% and a return on equity of 14.38%. The firm had revenue of $696.70 million for the quarter, compared to the consensus estimate of $642.68 million. During the same period in the previous year, the firm posted $1.03 EPS. The business’s quarterly revenue was down 3.6% on a year-over-year basis.

WARNING: This report was originally reported by Financial Market News and is the property of of Financial Market News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at http://www.financial-market-news.com/jefferies-group-research-analysts-decrease-earnings-estimates-for-albemarle-co-alb/1406134/.

Earnings History and Estimates for Albemarle (NYSE:ALB)

Other research analysts have also issued research reports about the stock. Robert W. Baird reissued an “outperform” rating and issued a $125.00 price objective on shares of Albemarle in a research note on Sunday, April 9th. Zacks Investment Research raised shares of Albemarle from a “hold” rating to a “buy” rating and set a $118.00 price objective for the company in a research note on Tuesday, April 4th. Royal Bank of Canada reissued a “buy” rating and issued a $132.00 price objective on shares of Albemarle in a research note on Tuesday. Citigroup Inc lowered shares of Albemarle from a “buy” rating to a “neutral” rating and raised their price objective for the company from $104.77 to $112.00 in a research note on Monday, March 6th. They noted that the move was a valuation call. Finally, Aegis initiated coverage on shares of Albemarle in a research note on Friday, February 17th. They issued a “buy” rating and a $108.00 price target for the company. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $111.00.

Albemarle (NYSE:ALB) traded down 0.27% during mid-day trading on Thursday, hitting $105.23. 908,745 shares of the stock were exchanged. The stock’s 50 day moving average is $104.69 and its 200 day moving average is $92.26. The stock has a market cap of $11.85 billion, a PE ratio of 18.51 and a beta of 1.41. Albemarle has a 52-week low of $65.57 and a 52-week high of $107.56.

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 3rd. Stockholders of record on Wednesday, March 15th were given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 1.21%. The ex-dividend date was Monday, March 13th. This is an increase from Albemarle’s previous quarterly dividend of $0.31. Albemarle’s payout ratio is currently 63.54%.

Hedge funds have recently modified their holdings of the company. State Street Corp increased its stake in Albemarle by 3.0% in the fourth quarter. State Street Corp now owns 6,326,177 shares of the specialty chemicals company’s stock valued at $544,643,000 after buying an additional 186,320 shares during the period. Jennison Associates LLC increased its position in shares of Albemarle by 218.8% in the third quarter. Jennison Associates LLC now owns 4,147,707 shares of the specialty chemicals company’s stock valued at $354,587,000 after buying an additional 2,846,734 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of Albemarle by 4.9% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 3,162,729 shares of the specialty chemicals company’s stock valued at $270,382,000 after buying an additional 148,484 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Albemarle by 5.3% in the third quarter. BlackRock Fund Advisors now owns 1,950,857 shares of the specialty chemicals company’s stock valued at $166,779,000 after buying an additional 98,715 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Albemarle by 5.1% in the third quarter. Northern Trust Corp now owns 1,312,071 shares of the specialty chemicals company’s stock valued at $112,169,000 after buying an additional 63,469 shares during the last quarter. Institutional investors and hedge funds own 86.50% of the company’s stock.

Albemarle Company Profile

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

5 Day Chart for NYSE:ALB

Receive News & Ratings for Albemarle Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle Co. and related companies with MarketBeat.com's FREE daily email newsletter.